Albert Chon is the Co-founder and Chief Technology Officer (CTO) of Injective Labs. Before Injective Labs, Chon worked with several tech companies including Linc Global and Amazon. ^[1][3]

Early Life and Education

Albert Chon completed a Master of Science in Computer Science with a focus on Systems at Stanford University. He also attained a Bachelor of Science in Computer Science with a specialization in Artificial Intelligence from the same institution. ^[2]

In high school, Albert took additional courses at Cerritos College and participated in the Summer Academy in Applied Science & Technology at the University of Pennsylvania, where he studied biotechnology. Albert achieved the distinction of being the valedictorian of his graduating class at Gretchen Whitney High School. ^[1][2]

Career

Albert Chon started his career as an Analytical Chemist and Marketing Associate at Advanced Botanical Consulting & Testing Inc. in 2014. Afterward, he moved to the role of a Marketing Copywriter & Technical Analyst at L3 Networks. He served as a Researcher at Stanford Parallel Distributed Processing Lab in 2016. ^[2]

In 2017, Chen became a Full Stack Software Engineer at Linc Global Inc. In 2018, he contributed as a consultant at Open Zeppelin and served as a Software Development Engineer at Amazon. In 2021, Chen became a Tendermint Fellow.^[2]

Injective Protocol

Albert Chon joined Injective Protocol as a Co-founder and Chief Technology Officer (CTO) in 2018 alongside Eric Chen. Injective Protocol is a layer-2 DEX (Decentralized Exchange) that supports advanced trading features such as margin trading and derivatives. ^[5]

In April 2021, Injective raised $10 million in a funding round with participation from billionaire entrepreneur Mark Cuban, Pantera Capital, BlockTower Capital, Hashed Ventures, CMS Holdings, and QCP Capital. ^[6]

In August 2022, Injective raised $40 million to accelerate the adoption and growth of Web3 finance. The funding round consisted of Jump Crypto and BH Digital (the crypto arm of famed hedge fund manager Alan Howard). ^[7]

Albert Chon in an interview describes Injective Protocol:

"A platform that is building a fully decentralized derivatives and spot exchange protocol. This protocol is being developed on top of the Cosmos SDK."^[8]